May 18, 2021 -- The G2 Bio Companies have launched to fund and develop gene therapy candidates from the University of Pennsylvania Gene Therapy Program.
G2 Bio Companies, which includes G2 Bio Management Company and affiliates, were founded by the University of Pennsylvania Gene Therapy Program and its director Dr. James Wilson, PhD, as well as Dr. Tachi Yamada and global investment firm Temasek. Yamada has founded numerous startup companies such as Phathom Pharmaceuticals and Passage Bio and has also served as chief medical and scientific officer at Takeda Pharmaceuticals and chairperson of research and development at GlaxoSmithKline.
Temasek has committed to invest $200 million in the G2 Bio Companies, which consist of the G2 Bio Management Company and affiliates.
Copyright © 2021 scienceboard.net